Karyopharm Therapeutics has agreed a merger with Ayrmid Ltd., the parent of Gamida Cell, under a restructuring support agreement and has filed for Chapter 11 protection to carry it out, the Massachusetts-based cancer drug company said on 2 November 2026.
Why Ayrmid Ltd. is buying Karyopharm Therapeutics Inc.
Ayrmid said it sees a strong strategic fit, with complementary portfolios and commercial capabilities in haematology, and potential in Karyopharm's marketed products, including XPOVIO (selinexor), and its development pipeline in multiple myeloma and myelofibrosis.
“We see a strong strategic fit between Ayrmid and Karyopharm, with complementary portfolios, established commercial capabilities and a shared commitment to addressing significant unmet needs in hematology,”
Deal terms and financing
The restructuring support agreement with existing lenders, noteholders and other stakeholders provides for a merger between Ayrmid and a reorganised Karyopharm, to be completed through a Chapter 11 plan. Ayrmid will be lead bidder, and the court will be asked to approve bidding procedures allowing competing proposals. Karyopharm has commitments for up to US$55m of debtor-in-possession financing. Financial terms of the merger were not disclosed.
Regulatory approvals and timing
The deal requires approval from the US Bankruptcy Court for the Southern District of Texas and is expected to close in the first quarter of 2027, subject to the conditions in the Chapter 11 plan.
Market context
Karyopharm markets XPOVIO in the US for relapsed or refractory multiple myeloma; the drug is approved as XPOVIO or NEXPOVIO in more than 50 other countries and territories. Ayrmid has two FDA-approved products, Omisirge and APHEXDA.
